Nevro Corp. (NYSE:NVRO – Get Free Report) has earned a consensus rating of “Reduce” from the thirteen research firms that are ...

Analysts at StockNews.com initiated coverage on shares of Nevro (NYSE:NVRO – Get Free Report) in a research note issued on ...

NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Alpha Teknova (TKNO – Research Report), Wave Life Sciences ...

Nevro (NVRO) delivered earnings and revenue surprises of 18.99% and 1.49%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Nevro behaalde een omzet van $ 105,5 miljoen voor het kwartaal, een daling van 9,1% op jaarbasis, maar boven de consensusverwachting van $ 100,18 miljoen. Het bedrijf rapporteerde echter een verlies ...

Investing.com - Nevro Corp (NYSE: NVRO) rapporteerde op dinsdag voor het eerste kwartaal een winst die lager is dan verwacht en een omzet die hoger is dan de voorspellingen.

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the ...

China and Mexico are two of the largest medical equipment manufacturers in the world. The U.S. has imported roughly $10B in ...

Nevro Corp (NYSE:NVRO) is set to release its Q4 2024 earnings on Mar 4, 2025. The consensus estimate for Q4 2024 revenue is ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Nevro Corp. (NYSE: NVRO)’s sale to Globus Medical for $5.85 per share. If you are a Nevro shareholder, click here to learn more about your rights and options. 180 Degree Capital Corp. (NASDAQ ...